Kymab is a biopharmaceutical company which discovers and develops human monoclonal antibody therapeutics. The Company focuses on using the Kymouse platform for the discovery, development, and commercialization of monoclonal antibodies to difficult and novel drug targets in various therapeutic areas. Its pipeline products cover immuno-oncology, immunology, and opportunistic therapeutic spaces.
|Employees (est.) (Sept 2021)||169||(+2%)|
Kymab total Funding
Kymab latest funding size
Time since last funding
|5 years ago|
|Wellcome Trust, Bill & Melinda Gates Foundation, Woodford Investment Management, Hepalink, Woodford Patient Capital, Malin, Malin Corporation plc, ORI Healthcare Fund|
|GBP||FY, 2011||FY, 2012|
Kymab has 1.11k Twitter Followers. The number of followers has increased 0.3% month over month and increased 2.4% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Kymab founded?
Kymab was founded in 2009.
Who are Kymab key executives?
Kymab's key executives are Simon Sturge, Anne Hyland and Glenn A Friedrich.
How many employees does Kymab have?
Kymab has 169 employees.
Who are Kymab competitors?
Competitors of Kymab include Histocell, Centurion and Intra-Cellular Therapies.
Where is Kymab headquarters?
Kymab headquarters is located at Meditrina Building 260 Babraham Research Campus, Babraham.
Where are Kymab offices?
Kymab has an office in Babraham.
How many offices does Kymab have?
Kymab has 2 offices.
Receive alerts for 300+ data fields across thousands of companies